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LYMPHOMA TISSUE*
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The presence of tumor specific antigens in
human malignancy has not been established
although some work has suggested this possibility
(1, 2, 3, 4, 5, 6, 7).
Gorer (8), Foley (9), Prehn and Main (10) and
Revesz (11) have demonstrated that some spon-
taneous and chemically induced tumors in ani-
mals contain antigens which are not present in
analagous normal tissue of similar genetic origin.
Habel (12) and Klein (13) have demonstrated
at least one specific antigen in tumors induced by
the polyoma virus.
In this study a horse was immunized with
mycosis fungoides tissue. Mycosis fungoides, a
disease of the reticulo—endothelial system, is a
lymphoma which has its origin in the skin but
which finally spreads to visceral organs similar to
other lymphomas. The horse sera was studied for
the presence of antibodies directed toward normal
skin tissue components and for specific antibodies
to mycosis fungoides tumor tissue. Small amounts
of immune horse serum and control horse sera
were injected into tumors and uninvolved skin
of patients with mycosis fungoides and into nor-
mal skin of other patients to determine the com-
parative reactivity of these tissues.
MATERIALS AND METHODS
Immunization procedure. A previously unim-
munized ten-year-old horse (Joe II) was utilized.
Tissue for injection was obtained from patients
in whom the diagnosis of mycosis fungoides had
been established. The tissue consisted of skin
tumors, and in two instances autopsy specimens
of visceral lymph nodes. The material was pre-
pared for injection as follows: 8mm punch biopsy
specimens of tumors were homogenized in the
cold in 3 cc of sterile saline with a Virtis "45"
* From the Dermatology Branch and **Patho
logic Anatomy Branch, National Cancer Institute,Bethesda, Maryland. National Institutes of
Health, Public Health Service, U. S. Department
of Health, Education and Welfare.
'Present address: Department of Dermatology,
Massachusetts General Hospital.
Presented at the Twenty-fourth Annual Meet-
ing of The Society for Investigative Dermatology,
Inc., Atlantic City, N. J., June 20, 1963.
tissue homogenizer. This homogenate was in-jected subcutaneously into the horse. The wet
weight of injected tumor tissue varied between
200 mg and 3 grams. One lymph node specimen,
prepared similarly, weighed approximately 2
grams while the second node weighed 4 grams.
Dates of tissue injections and blood withdrawal
are listed in Chart I. On two occasions the tumor
homogenate was mixed with Freund's complete
adjuvant, and also injected subcutaneously.
Control sera were obtained from a normal horse(Brenda) and from a horse (Blue Jacket) re-
peatedly injected over a month period with whole
human serum, plus complete and incomplete
Freund's adjuvant.
Complement fixation tests. Complement fixation
tests were done according to the method of Kent
and Fife (14). The horse serum was heated to 56°
for 30 minutes prior to making dilutions. Mycosis
fungoides tumors and normal skin, used as anti-
gens in this technic, were obtained with a 6 mm.
biopsy punch. These were homogenized as de-
scribed above. By routine grid titration it was
established that a 1 to 3 dilution of horse serum
was anti-complementary in this system. The
optimum dilution of aotigen was a 1 to 3 dilution
of a homogenate containing approximately 100
mg of wet weight tumor tissue per ml of homog-
enate. Each CF tube therefore contained 0.3 ml
of antigen homogenate, or approximately 11 mg of
tissue. Five-percent-hemolytic units of comple-
ment were used in the test. Complement fixation
tests were performed between the horse scm and
the following antigens: mycosis fungoides tumor
tissue, normal skin, normal lymph nodes and
normal human serum.
Immuno-diffusion; Precipitin tests were done by
the Ouchterlony method (15). Sera from Joe II, as
well as serum from the control horse Brenda, were
tested against tbe same above antigenic materials.
Immunoelectrophoresis according to the method
described by Potter (16) was performed using
these antigen-antibody combinations.
Fluorescent antibody technic. Horse sera from
Joe II and Brenda were conjugated with fluores-
cein isothioeyanate (17, 18). Tissue sections were
cut with a Spencer rotary mierotome in a eryostat
and prepared for study by the conventional Coons
technic (19). The tissue sections were 6 microns
in diameter. Rhodamine labelled bovine serum
albumin was used as a background stain to reduce
natural fluorescence in all specimens. Tissues
examined for uptake of fluorescein labelled horse
sera included the following: mycosis fungoides
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CHART I
INJECTION RECORD OP JOE II
skin tumors, mycosis fungoides lymph nodes,
normal lymph nodes, dermatopathie lymph nodes,
psoriatic skin, skin tumors of reticulum cell
sarcoma, metastatie carcinoma to the skin and
normal skin.
Intradermel injections of horse zero in patients.
In all patients intradermal injections of 0.1 cc of
the following sera were given: serum Joe II, drawn
4/24/62 and 11/8/61; normal horse serum (Brenda);
serum from horse immunized with human whole
serum (Blue Jacket). In all but two patients the
sites of injections were on the forearms. The test
sites were observed and photographed at 4, 24,
and 48 hours.
Normal skin of patients with cancers other than
mycosis fungoides and uninvolved skin of pa-
tients with psoriasis or basal cell tumors, was
used for control injections. Ta the patients with
mycosis fungoides, the above sera were injected
into both the uninvolved skin and into tumors.
In two patients large tumors of mycosis fun-
goides were injected at multiple sites, each site
receiving 0.1—0.2 cc of Joe II horse serum.
RESULTS
Complement fixation tests. Sera from Joe II
fixed complement in the presence of mycosis
fungoides skin tumor tissue; it did not fix com-
plement in the presence of normal skin or human
serum. There was reactivity with two out of five
homogenates of normal lymph nodes. No sig-
nificant reactivity with normal lymph node
tissue or human serum was noted.
The data in Chart IT indicate that the sera
Date of
Iejectioo
Wet Weight of
Material Injected Type ofMaterial Date BloodDrawo** Patleot Soorre
5/23/60
6/2/60
6/9/60
6/23/60
6/30/60
6/30/60
7/21/60
7/28/60
7/28/60
9/21/60
10/20/60
3/13/61
6/13/61
8/11/61
9/14/61
9/14/61
10/30/61
10/30/61
3/16/62
3/26/62
4/5/62
4/13/62
4/19/62
7/21/62
7/31/62
9/24/62
1/28/63
2/11/63
2/28/63
3/12/63
4/18/63
4/24/63
500 mgm
500 mgm
500 mgm
500 mgm
259 mgm
250 mgm
2000 mgm
500 mgm
500 mgm
4000 mgm
500 mgm
500 mgm
500 mgm
500 mgm
500 mgm
500 mgm
3000 mgm
3000 mgm
500 mgm
500 mgm
500 mgm
500 mgm
500 mgm
200 mgm
250 mgm
250 mgm
500 mgm
500 mgm
500 mgm
500 mgm
500 mgm
500 mgm
M.F. skin plaque
M.F. skin plaque
M.F. skin plaque
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
Visceral lymph node
M.F. tumor tissue
M.F. tumor tissue
Visceral lymph node
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue*
M.F. tumor tissue*
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue
M.F. tumor tissue*
June 28, 1960
Nov. 8, 1961
April 27, 1962
July 26, 1962
August 4, 1962
Sept. 29, 1962
April 23, 1963
April 29, 1963
E. S.
E. S.
E. S.
B. E.
P.S.
C. C.
B. E.
H.W.J.
P.S.
H.W.S.
T. J. D.
J. H.
M. E.
E. F.
E. F.
W. T.
W. T.
M. H.
N. K.
J. E.
J. E.
J. F.
F. D.
F. D.
E. D.
E. D.
P. P.
L. L.
0. H.
H. B.
H.P.
H.P.
* Injected homogenate mixed with Freund's complete adjuvant.
** Sera were frozen at —20C° until used.
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drawn on 11/8/61, 4/27/62, 4/23/63 and 4/29/63
were most reactive with tumor tissue. Correla-
tion of these data with the injections of tumor
tissue suggests that this high reactivity followed
multiple injections of tumor given over a short
period of time and/or single injections when the
tumor homogenate had been mixed with complete
Freund's adjuvant
Joe II horse scra were exposed to nine different
tumor homogenates. Five of the nine had a CF
titer of 1:25 or greater (Chart II). Only two
tumor homogenates were completely negative
when exposed to Joe II horse sera.
Joe II sera plus normal skin homogenates
from five different mycosis fungoides patients
failed to fix complement. Joe II serum of 4/24/62
CHART II
Patient serum vs Immune serum
November 8, 1961 1/24/63 Eakes Serum 1:3 <1:6
* Reactive indicates 60% or less hemolysis of red cells in the hemolytic system; weakly reactive indi-
cates 65—90% hemolysis; non-reactivity, 90—100% hemolysis.
** A single test performed with 2.5 unit complement. Remainder of tests performed with 5 unit
complement.
Complement Fixation Tests (Antigen Mycosis Fungoides Tumor)
Serum Specimen
of Joe II
Date of
Test
Patient
(Antigen Source)
Dilution of
antigen(Skin Tumor)
Horse Sera
reactive*
June, 1960
November, 1961
November, 1961
November, 1961
November, 1961
November, 1961
November, 1961
November, 1961
November, 1961
November, 1961
March 8, 1962
March 8, 1962
March 8, 1962
April 24, 1962
April 24, 1962
April 24, 1962
April 24, 1962
April 24, 1962
April 24, 1962
April 24, 1962
July, 1962
October, 1962
October, 1962
October, 1962
April 23, 1963
April 23, 1963
April 29, 1963
April 24, 1962
November, 1961
November, 1961
November, 1961
November, 1961
5/3/63
5/8/63
2/14/63
2/7/63
1/30/63
2/22/63
2/27/63
2/27/63
5/13/63
5/3/63
1/30/63
4/10/63
4/5/63
7/12/62
7/19/62
8/17/62
9/24/62
12/21/62
1/22/63
1/22/63
5/3/63
1/22/63
12/21/62
1/22/63
5/8/63
5/3/63
5/3/63
1/24/63
2/7/63
5/13/63
8/15/63
10/8/63
H.P.
H.P.
L. L.
L. L.
P. P.
H. B.
H. B.
0. R.
A. L.
H.P.
P. P.
P. P.
H.P.
E. D.**
E. D.
D. D.
J. E.
J. F.
J. E.
P. P.
H.P.
P. P.
J. F.
J. E.
H.P.
H.P.
H.P.
Normal lymph node
Normal lymph node
Normal node (surgical
specimen)
Normal lymph node
Normal lymph node
1:3
1:3
1:3
1:5
1:3
1:6
1:5
1:5
1:3
1:5
1:3
1:3
1:3
1:5
1:5
1:5
1:5
1:5
1:3
1:3
1:3
1:3
1:5
1:3
1:5
1:3
1:3
1:3
1:3
1:3
1/2
1/2
1:27
1:81
<1:3
not reactive
1:25
not reactive
not reactive
<1:10
1:100
1:9
1:25
not reactive
not reactive
1:81
1:10
1:3
1:3
1:3
1:25
1:25
1:27
<1:5
not reactive
<1:5
1:27
1:162
1:162
<1:6
not reactive
anti-complementary
1/160
1/40
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CHART III
Complement Fixation Tests (Normal Skin)
Serum Specimen
of Joe II Date of Test
Patient
(Antigen Source)
Dilution of
Antigen Sera Reactive
11/8/61 2/7/62 L. L. 1/5 not reactive
11/8/61 2/14/63 L. L. 1/3 not reactive
11/8/61 2/22/63 H. B. 1/6 not reactive
11/8/61 2/27/63 H. B. 1/5 not reactive
11/8/61 2/27/63
October, 1962 I 1/22/63
October, 1962 1/22/63
4/24/62 1/22/63
4/24/62 1/22/63
0. R.
P. P.
J. E.
J. B.
P. P.
1/5 not
1/3 not
1/3 not
1/3 not
1/3 not
reactive
reactive
reactive
reactive
reactive
was negative when exposed to normal skin ac-
quired from surgical biopsy of a normal patient
(not listed in Chart III).
Attempts to eliminate complement fixing
reactivity from the sera of Joe II by absorption
with human serum, normal skin, normal lymph
node and skin tumors of mycosis fungoides have
been unsuccessful by technics employed to date.
Immuno-cliffusion tests. Prccipitin tests (Ouch-
terlony revealed a single diffuse band when the
serum from Joe 11(6/23/60, 8/16/61, 11/8/61,
4/24/62) was tested against the whole serum
from a group of patients consisting of two normal
controls, six mycosis fungoides patients and two
patients with other malignant diseases. The
control horse serum (Brenda) was negative when
exposed to all sera.
Joe II horse serum was tested against nine
homogenates of mycosis fungoides tissue and
against one normal skin homogenate. A single
precipitin band was present between Joe II
horse serum and homogenates of mycosis fun-
goides tumors and absent with the homogenate
of normal skin. These bands were identical to
those demonstrated between Joe II horse serum
and normal human serum.
Immunoelectrophoresis in which Joe II (11/-
8/61) was diffused against human serum which
had been electrophoresed resulted in immuno-
precipitate arcs characteristic of a2 globulin,
beta lipo protein, siderophilin and albumin.
Tests between Joe II (11/8/61) and mycosis
fungoides tumor homogenates, as well as normal
skin homogenates, revealed similar bands (Fig-
ure 1).
Fluorescent antibody studies. Horse sera from
Joe 11(11/8/61 and 6/28/60) were conjugated
FIG. 1. Code for Picture on Immuno-Electro-
phoresis:
1. Anti-human rabbit serum.
2. Joe II serum (11/8/61).
3. Anti-human rabbit serum.
4. Joe II serum (11/8/61).
5. Anti-human rabbit serum.
6. Joe II serum (11/8/61).
7. Anti-human rabbit serum.
A. Van Scott (Normal human serum).
B. Tilman serum (11/20/61) Mycosis fungoides.
C. Dunkle serum (9/11/61) Multiple myeloma.
D. Field serum (11/20/61) Normal human
serum.
B. Fisher serum (9/28/61) Macroglobulinemia.
F. Knight serum (10/4/61) B2A Peak.
Name of
Patient
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CHART IV
Fluorescent Antibody Results in Skin from Patients with Mycosis Funyoides and Other Skin Diseases
Diagnosis
1. rhBSA*
2. Non-in-
moor Joe II
1. rSBSA
2. Brenda
1. rhBSA
2. Immune
Joe It
1. N. Cooj. Im-
mune Joe TI
2. rhBSA
3. tmmune Joe TI
S. —
C. —
S. —
C. —
S. —
C. —
S. —
C. —
S. —
C. —
S. —
C. —
C. —
S. —
C. —
S. —
C. —
S.
C. —
S. —
C. —
S. —
C. —
S. —
H. P. M.F.
H. P. Normal skin
CT. M.F.
C. T. Normal skin
H. B. M.F.
H. B. Normal skin
H. P. M.F.
H. P. Normal skin
C. S. M.F.
C. S. Normal skin
L. L. M.F.
L. L. Normal skin
A. L. M.F.
W. J. Psoriasis
H. P. M.F.
Lo. Li. Lymphoma Cutis
L.L. M.F.
K. C. Motastatic Car-
cinoma
S. +
C.
S. +
C. —
S. +
C.
S. +
C. —
S. +
C.
S. +
C. —
S. +
C. +
C. —
S.
S. +
C. +
S. +
C.
S. +
C. +
C. —
S. —
S. +
C. +
S. +
C.
S. +
C. +
S. +
C. —
S. +
C. +
S. +
C. —
1. N.Conj. non-
immune Joe II
2. rhBSA
3. Immune Joe II
S. +
C. +
S. +
C.
S. +
C. +
S. +
C. —
S. +
C. +
S. +
C. —
S.
C. —
S.
C. —
S.
C. —
S.
C. —
S.
C. —
S.
C. —
C. —
S. —
S.
C. —
C. —
S. —
S.
C. —
C. —
S. —
S.
C. —
S.
C.
S.
C. —
S.
C. —
S.
C. —
S.
C. —
S. —
C. —
S. +
C. —
S. +
C. —
S. —
C. —
S. —
C. —
* rhBSA = rhodamine bovine serum albumin.
N. Conj. = Non-conjugated.
C. = Cytoplasm of cells in dermal infiltrate.
S. = Stroma.
with fluorcscein isothiocyanate. A normal horse
serum, Brenda, was also conjugated.
All sections of normal skin, mycosis fungoides
tumors, psoriasis, and reticulum cell sarcoma
revealed stromal fluorescence following exposure
to fluorescein conjugated scm of Joe 11(11/8/61)
(Chart IV); this was not completely removed by
initially applying the same serum unconjugated.
+ = positive fluorescence
— = no fluorescence
weak or questionable fluorescence
No fluorescence was seen when these tissues were
exposed to conjugated normal horse serum.
In addition to stromal fluorescence, the periph-
eral rim of cytoplasm of the cells in the dermal
infiltrate in mycosis fungoides tumors fluoresced
when exposed to conjugated Joe II serum of
11/8/61; this fluorescence was not observed when
sections were successively treated with uneon-
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CHART V
Fluorescent Antibody Studies: Lymph node vs Immune Joe II, November 1961
jugated Joe II of 11/8/61 and the conjugated
antiserum in a standard inhibition procedure.
No fluorescence was seen with conjugated Joe
II of 6/28/60 or with conjugated normal horse
serum.
No definite cellular fluorescence in normal skin,
mctastatic carcinoma in skin, reticulum cell
sarcoma in skin nor the inflammatory cells in
psoriasis was detectable when exposed to the
conjugated Joe II scra or conjugated normal
horse serum.
Sections from six lymph nodes from different
patients were exposed to conjugated Joe II,
11/8/61 and conjugated normal horse serum
(Chart V). The stroma in all six nodes fluoresced.
The peripheral rim of cytoplasm of reticulum
cells fluoresced in three nodes, two of which were
from a patient with mycosis fungoidcs; the
third was a normal node from a patient having
a pheochromocytoma.
IN Vi vo SKIN TESTING
Normal skin. Horse sera of Joe II (11/8/61
and 4/24/62) normal horse serum (Brenda),
and horse anti-human whole serum (Blue Jacket)
were used in routine intradermal skin tests. One-
tenth ml of each was injected into uninvolved
skin of the forearm of each patient. Five of
seven normal controls were sensitive to normal
horse serum. Two controls who were not sen-
sitive to normal horse serum reacted positively
to Joe TI, demonstrating an area of induration
approximately 2 cm in diameter at the site of in-
jection 24 hours later. A slight reaction, iden-
tified as an area of induration 4—6 mm in di-
ameter, was noted at 24 hours at the site
injected with Blue Jacket's serum.
Uninvolved skin of patients having mycosis
fungoides. The uninvolved skin of nine of these
patients were skin tested in the same manner
as above. Only one patient with mycosis fun-
goides was sensitive to normal horse serum.
Eight patients reacted to Joe II with 10—20 mm
of induration, and to Blue Jacket with 4—6 mm
of induration.
Mycosis fungoides skin tumors. Small mycosis
fungoidcs tumors (2—3 cm in diameter) were
injected with one-tenth ml of Joe 11(4/24/61)
horse serum, normal horse serum and horse anti-
human whole serum. Tumors injected with
normal horse serum did not react while those
injected with Blue Jacket developed slight scaling
at the site of injection at 5 days. Tumors in-
jected with Joe II serum developed a bluish
discoloration of the lesions at 4 hours and frank
necrosis at 24 hours. At 48 hours a small ulcer
Patient
1. rhBSK'
2. Conj.
Joe IP
1. rhBSA
2.Brenda' ConjugatedJoe II ConjugatedBrenda Patient Diagnosis Diagnosis onLymph Node
C. T.
H. K.
H.P. F.
C. S.
H.P.
0. H.
S. +
C. +
S. +
C. —
S. +
C.
S. +
C. —
S. +
C. —
S. +
C.
S. —
C. —
S. —
C. —
S. —
C. —
S. —
C. —
S. —
C. —
S. —
C. —
S. +
C. +
S.
C. —
Mycosis
Fungoidcs
Tcrato
Carcinoma
Phcochromo
cytoma
Mycosis
Fungoidcs
Mycosis
Fungoides
Mycosis
Fungoidcs
S. —
C. —
S. —
C. —
Dermatopathic
lymph adenopathy
Terrato Carcinoma
in part of node
Normal lymph node
M.F. in the node
(Hodgkin type)
Dcrmatopathic
lymph adenopathy
Reticulum cell Sar-
coma
C. = cytoplasm of cells in dermal infiltrate.S. = Stroma in all tissues.
X = Rhodamine bovine serum albumin is a dye that attaches to protein and blocks nonspecific or
auto-fluorescence.y = All tagged sera were labelled with Fluorcscein Isothiocyanatc and absorbed with liver powder.
= Brenda is conjugated normal horse serum.
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FIG. 2. A. Mycosis fungoides tumor prior to injection of Joe II horse serum (11/8/61). B. Same tumor
5 days after injection of 0.1 cc of Joe II horse serum (11/8/61).
was present in the center of the injected tumor, after the injections the bulk of each tumor was
Five days later this ulcer had reached a diameter necrotic.
of 0.5—1.0 cm and was filled with a dark serous
crust. (See Figs. 2, 3) DISCUSSION
In two patients large tumors (3—4 cm in di-
ameter) were injected at 3—4 sites with 0.1-0.2 cc
of Joe II horse serum per site. Marked necrosis
of the tumor was noted at 48 hours. One week
Two possibilities may explain the finding that
immune serum of Joe II fixes complement in the
presence of homogenates from mycosis fungoides
tumors while less reactivity occurs in the pres-
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FIG. 3. A. Two small mycosis fungoides tumors prior to injoction of Joe II horse serum. B. Same
tumor 5 days after injection of horse serum. The superior lesion was injected with 0.1 cc of normal
horse serum (Brenda). The inferior lesion was injected with 0.1 cc of horse anti-human whole serum
(Blue Jacket).
ence of normal skin, lymph node or human
serum. The first is the possibility that tumor
tissue undeed contains different antigens than
the normal tissue and serum tested. The second
is the possibility that the antigenic components
of both tumor tissue and normal tissue are
similar, but that tumor tissue contains one or
more of these antigens in large quantity. In the
latter case, failure to depress the complement-
fixing titer against tumor following absorption
with normal tissue may be due to the small
amount of antigen in normal tissues. Such a
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possibility perhaps can be ascertained by uti-
lizing quantitative complement fixation tests.
The immune horse serum from Joe II contains
precipitin antibodies to normal human serum
components including a2 globulin, beta lipo
protein, siderophilin and albumin. The precipitin
antibodies demonstrated against mycosis fun-
goides tumor homogenates seem to be identical
to those precipitating human serum components.
The fact that significant precipitin antibodies
against human gamma globulin were rIot detected
remains unexplained.
The fluorescent antibody studies indicate that
the serum of Joe II contains, in addition to a
stromal antibody, an antibody directed against
the cytoplasm of cells present in the mycosis
fungoides tumors. The latter seems to be on an
immune basis since it was not detectable follow-
ing the inhibition procedure. Although skin in-
filtrates of several other lesions tested fail to
show cytoplasmic fluorescence, additional lesions
containing cells similar to ones noted in mycosis
fungoides tumors must be examined with the
fluorescent antibody technic before it can finally
be concluded that this reaction demonstrates
the presence of a tumor specific antigen.
The immune horse serum from Joe II produces
necrosis of mycosis fungoides tumors in vivo.
This reaction is very rapid, occurring in four
hours and is similar to an Arthus reaction, which
represents a vascular response or antigen-anti-
body reaction. It would not seem to be due to non-
specific irritation by the serum since no such
necrosis of tumors occurred following injection
with normal horse serum.
SUMMARY
Preliminary investigations demonstrated that
serum from a horse injected with mycosis fun-
goides tumor homogenates fixed complement in
the presence of homogenates of similar tumors;
fixation was absent or reduced with homogenates
of normal skin, normal lymph node and with
human serum.
A common precipitin band between this horse
serum and homogenates of mycosis fungoidcs
tumor and normal skin seemed identical to the
bands occurring between the horse serum and
normal human serum.
Fluorescent antibody studies indicate a stromal
antibody in Joe II horse serum which was reactive
in all tissues exposed to the serum. In addition an
antibody against the cytoplasm of cells in mycosis
fungoidcs tumors was demonstrable.
Small amounts of Joe II serum injected into
mycosis fungoidcs tumors produced necrosis in
the first twenty four hours. Necrosis was not
seen when small amounts of normal horse serum
were injected into similar tumors.
Possible explanations of these findings are
presented.
REFERENCES
1. SOUTHAM, CHESTER M.: Relationships of
immunology to cancer: A review. Cancer
Res., 20: 271, 1960.
2. GRAHAM, J. B. AND GRAHAM, R. M.: Anti-
bodies elicited by cancer in patients. Cancer,
8: 409, 1955.
3. SOUTHAM, C. M. AND MOORE, A. E.: Induced
immunity to cancer cell homographs in
man. Ann. N. Y. Aead. Sci., 73: 635, 1958.
4. BJORKLUND, BERTIL AND BJORKLUNO, VIvEKA:
Antigenicity of pooled human malignant
and normal tissue by cyto-immunological
technique. Tnt. Arch. Allerg., 10: 153, 1957.
5. BJORKLUND, BERTIL: A serum eytolytic
factor active against HeLa and other estab-
lished cell strains. Proc. Soc. Exp. Biol.
Med., 103: 1, 1960.
6. BJORKLUND, BERTIL, LUNDBLAD, GUNNAR
AND BJORKLUND, VIvEKA: Antigenieity of
pooled human malignant and normal tissues
by eyto-immunologieal technique: IT. Na-
ture of tumor antigen. Tnt. Arch. Allerg.,
12: 241, 1958.
7. BJORKLUND, BERTIL: Effect of horse anti-
human cancer serum on malignant and
normal human cells. Tnt. Arch. Allerg.,
10: 56, 1957.
8. CORER, P. A., TUFFREv, MAUREEN A. AND
BATcHELOR, J. R.: Serological studies on
the x-antigens. Ann. N. Y. Aead. Sei., 101:
5, 1962.
9. FOLEy, E. J.: Antigenic properties of methyl
cholanthrene-indueed tumors in mice of
the strain of origin. Cancer Res., 13: 835,
1953.
10. PREEN, R. T. AND MAIN, J. M.: Immunity
to methyl eholanthrene-indueed sarcomas.
J. Nat. Cancer Inst., 18: 769, 1957.
11. Rvmz, L.: Detection of antigenic difference
in isologous host-tumor systems by pre-
treatment with heavily irradiated tumor
cells. Cancer Res., 20: 443, 1960.
12. HAHn, K.: Immunological determinants of
polyoma virus oneogenesis. J. Exp. Med.,
115: 181, 1962.
13. STORGREN, H. 0., HELL5TROM, I. AND KLEIN,
C.: Transplantation of polyoma virus in-
duced tumors in mice. Cancer Res., 21:
329, 1961.
14. KENT, JOHN F. AND FIFE, EARL H., JR.:
Precise standardization of reagents for
complement fixation. Amer. J. Trop. Med.,
12: 103, 1963.
15. OUcHTERLONv, OHJAN: In vitro method for
testing the toxin producing capacity ofdiphtheria bacteria. Aeta Path. Microbiol.
Seand., 25: 186, 1948.
438 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
16. POTTER, MICHAEL AND KIJFF, EDWARD L.:
Myeloma globulins of plasma cell neoplasms
in inbred mice. I. Immunoelectrophoresis of
serum, with rabbit antibodies prepared
against microsome fractions of the neo-
plasms. J. Nat. Cancer Inst., 26: 1109, 1961.
17. FRLTON, LLOYD C. AND Mc MILLION, ROBERT
C.: Chromatographically pure fluorescein
and tetramethyl rhodamine isothiocyanates.
Anal. Biochen. 2: 178, 1961.
18. HIRAMOTO, RAYMOND, ENOEL, KARL AND
PRESSMAN, DAVID. Tetramethyrhodamine
as immunohistochemical fluorescent label
in the study of chronic thyroiditis. Proc.
Soc. Exp. Biol. Med., 97: 611, 1958.
19. COONS, A. H.: Fluorescent antibody methods.
General Cylochemical Methods, Vol. 1. In
Danielli, J. F. (ed.): New York, Academic
Press, 1958.
DISCUSSION
Dn. HERBERT ME5CON (Boston, Mass.): I
would like to ask whether you have been able
to isolate, or have you any ideas about, which
fraction of the tumor is the antigenie one for
the horse? In your slide the stroma stains;
apparently this is connective tissue. Why do the
tumor cells stain as well, perhaps, as some non-
tumor cells. Did the epidermis stain? Were your
homogenates that were injected into the horse
only dcrmal homogenates or total skin homog-
enates?
I think this approach to tumors, on an immuno-
logical basis, is one that needs considerable ex-
ploration, and maybe one way of eventual treat-
ment in the future. You all are probably familiar
with the work that has been done in trying to
create antibodies to whole tissue. As a tumor be-
comes more and more malignant and less and less
differentiated, it loses its antigenic similarity
with the tissue from which it was derived. This
may explain why malignant tumors normally
spread so easily, in so far as they may have not
created antibodies. It is interesting that mycosis
fungoides is a relatively slow spreading tumor,
or at least people live a long time with it. Are
these patients able normally to produce any anti-
bodies to their own tumor?
Dn. LYON P. STREAN (Norristown, Pa.): I
would like to ask whether these complement-
fixing antibodies were developed following a
single subcutaneous injection or upon completion
of a precise course of multiple injections, a pro-
cedure commonly employed in the production
of diphtheria or tetanus antitoxin? Secondly,
were other animals immunized, such as the
rabbit?
Dn. W. KENNETH BLAYLOCK (in closing): I
wish to thank the discussers for their interesting
comments and questions.
Dr. Mescon's question about the antigens in
the mycosis fungoides is a good one. There are
numerous antigens in the mycosis fungoides
homogenate. We have not chemically separated
these antigens to inject them into an experimental
animal, but we do plan to do this particular
procedure in the future. The epidermis does
fluoresce nonspecifically when using conjugated
immune sera, but with the rhodamine background
stain this is reduced markedly. The homogenate
contains both epidermis and dermis and this was
obtained with an S mm punch biopsy of the
mycosis fungoides tumor.
Dr. Strean's question about CF antibody
titers is pertinent. The immune horse was injected
approximately 30 times. There was an initial
rise in the antibody titer after one month. This
dropped to normal and then an amnestic response
was noted with subsequent injections of the myco-
sis fungoides homogenate. Rabbits were injected
with the mycosis fungoides homogenates. No
antibody response was noted when these animals
were used.
